ACXP - CIK 0001736243
Acurx Pharmaceuticals, Inc. (ACXP) reported net income of -$7.97M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$7.97M | +43.5% |
| FY 2024 | -$14.10M | +3.3% |
| FY 2023 | -$14.58M | -20.5% |
| FY 2022 | -$12.09M | +5.1% |
| FY 2021 | -$12.75M | -177.1% |
| FY 2020 | -$4.60M | - |
Acurx Pharmaceuticals, Inc. (ACXP) reported net income of -$7.97M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Acurx Pharmaceuticals, Inc.'s net income declined from -$4.60M to -$7.97M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.